Free PSA Test Awarded US Patent

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

ABBOTT PARK, Ill--Abbott Laboratories and the Finnish-based company Wallac Oy, a subsidiary of EG&G Inc. (Wellesley, Mass), have received a US patent for two methods of assaying free PSA (prostate-specific antigen).

ABBOTT PARK, Ill--Abbott Laboratories and the Finnish-based companyWallac Oy, a subsidiary of EG&G Inc. (Wellesley, Mass), havereceived a US patent for two methods of assaying free PSA (prostate-specificantigen).

The patent was issued to two inventors, Dr. Ulf-Hakan Stenman,of Helsinki University Central Hospital, and Dr. Hans Lilja, ofLund University.

The inventors gave exclusive rights to Wallac, which subsequentlygranted a sublicense to Abbott. The patent covers immmunoassaysfor free PSA and the use of the ratio of free-to-total PSA tobetter distinguish between prostate cancer and benign prostatichyperplasia (BPH).

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content